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Breast cancer is one of the major healthcare challenges in South 
Africa (SA). Data published by the National Cancer Registry[1] 
in 2014 showed that breast cancer represented 22% of all cancers 
affecting women in SA, making it the most prevalent cancer affecting 
women in this country. Understanding the total cost of care for 
breast cancer is important from a health funder perspective, i.e. 
policymakers and hospital administration, in budget allocation and 
in decision-making[2] in a resource-constrained environment.
Objectives
To develop a method to determine the cost of breast cancer treatment 
with chemotherapy per episode of care and to quantify the associated 
costs relating to chemotherapy at Groote Schuur Hospital (GSH), a 
tertiary government hospital in Western Cape Province, SA. These 
costs included costs associated with the management of adverse 
events arising from chemotherapy.
Methods
Study design
A retrospective cohort analysis was performed to determine the 
cost of an episode of care for treatment of breast cancer with 
chemotherapy. Cost estimates for an episode of care were obtained 
for each stage of breast cancer. The episode of care was defined as 
the care provided from 2 months prior to the date of commencing 
chemotherapy (pre-chemotherapy phase), during chemotherapy 
(treatment phase) and until 6 months after the date when the last 
cycle of chemotherapy was administered (follow-up phase). The 
episode of care was on average a period of 10 - 12 months per patient.
Participants
A total of 1 024 patients were extracted from the electronic database. 
Two hundred patients were randomly selected using a random 
number generator. Patients were included in the study based on the 
following criteria: (i) a diagnosis of breast cancer; (ii) registration 
date at the oncology department from 1 April 2013 to 31 March 
2015; (iii) evidence of receipt of chemotherapy with two or more 
health encounters[3] related to breast cancer, e.g. doctor consultation 
in oncology ward and a mammogram; and (iv) age ≥18 years. 
Patients were excluded from the study based on the following criteria: 
(i)  male; (ii) initiated on hormone therapy but not chemotherapy; 
(iii) enrolled in a clinical trial; and (iv) a primary diagnosis of cancer 
that was not breast cancer.
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Background. There has been no comprehensive study determining the financial burden of breast cancer in the South African (SA) public sector.
Objectives. To develop a method to determine the cost of breast cancer treatment with chemotherapy per episode of care and to quantify 
the associated costs relating to chemotherapy at Groote Schuur Hospital (GSH), a government hospital in SA. These costs included costs 
associated with the management of adverse events arising from chemotherapy.
Methods. Retrospective patient-level data were collected for 200 patients from electronic databases and patient folders between 2013 
and 2015. Direct medical costs were determined from the health funder’s perspective. The information collected was categorised into the 
following cost components: chemotherapy medicines, support medicines, administration of chemotherapy, laboratory tests, radiology 
scans and imaging, doctor consultations and adverse events. Time-and-motion studies were conducted on a set of new patients and the 
data obtained were used for the study sample of 200 patients. All the above costs were used to determine the cost of chemotherapy per 
episode of care. The episode of care was defined as the care provided from 2 months prior to the date of commencing chemotherapy (pre-
chemotherapy phase), during chemotherapy (treatment phase) and until 6 months after the date when the last cycle of chemotherapy was 
administered (follow-up phase).
Results. A method was developed to determine the episode-of-care costs for breast cancer at GSH. The total direct medical cost for treatment of 
breast cancer at GSH for 200 patients was ZAR3 154 877, and the average episode-of-care cost per patient was ZAR15 774. The average cost of 
management of adverse events arising from the various treatment modalities was ZAR13 133 per patient. It was found that the cost of treating 
a patient with adverse events was 1.8 times higher than the cost of treating a patient without adverse events. Of the patients, 86.5% managed 
to complete their prescribed chemotherapy treatment cycles, and the average cost of treatment of these patients was 1.3 times more than the 
average cost for patients who could not complete their treatment, based on the number of treatment cycles received.
Conclusion. A comprehensive method to determine the costs associated with breast cancer management per episode of care was developed, 
and costs were quantified at GSH according to the treatment protocol used at the hospital.
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Setting
The study site was GSH, a tertiary government hospital in the 
Western Cape.
Development of method
Patient information obtained from the folders was recorded on data 
collection forms. In instances where patient folders were missing 
during the data collection period, another patient folder was randomly 
selected to replace the missing folder. The associated electronic patient 
profile was also extracted. Each patient in the study had electronic and 
folder data collected.
The electronic database provided the following information: 
(i)  patient demographics, i.e. name, surname and hospital number; 
(ii) medicine profile, which included the name, date of issue, quantity 
issued and cost of each chemotherapy medicine; (iii) support medicines, 
which included the name, dose, cost and date of issue of each medicine; 
(iv) laboratory tests, which included the name of the test, number of 
tests performed and date when the test was performed; (v) scans and 
imaging data, which included the name, number and date of scans and 
imaging performed; (vi) consultations, which included scheduled and 
emergency visits, date of consultation and department attended by the 
patient; and (vii) inpatient hospitalisation data, which included the date 
of admission, date of discharge, duration of stay, ward type and reason 
for admission.
The patient folders provided data to supplement the information 
obtained from the electronic database. Folder information was used 
to verify the electronic data. Additional information received from the 
folders included age at diagnosis, date of registration in the Radiation 
Oncology Department, stage of disease, weight, height and body surface 
area. Detailed clinical information collected included the histo logical 
type of disease, comorbidity, treatment intent, hormone receptor status, 
doctors’ notes on the consultations, and adverse events data, which 
included the date when the event occurred, associated emer gency 
consultation, inpatient hospitalisation and reason for admission.
Costing method
Only direct medical costs and resource use relating to chemotherapy 
in the management of breast cancer at GSH were used in this study. In 
addition, the costs of management of adverse events were determined. 
The various cost components were aggregated for calculation of the 
total cost of an episode of care.
The sources of costs used in this study were the Medical Informatics 
electronic database, the JAC Medicines Management system, the 
Uniform Patient Fee Schedule (UPFS),[4] and time-and-motion 
studies. The facility and professional fees for administration of chemo-
therapy, scheduled outpatient consultation, emergency outpatient 
consultation, inpatient hospitalisation, scans and imaging, and 
laboratory tests were obtained from the UPFS. The UPFS was also the 
source of the medicine dispensing fee and the cost of drawing blood 
for laboratory tests. According to the UPFS, the single professional 
fee consisted of the cost of the doctors, nurses and other healthcare 
professionals involved in the care of the patient. The facility fee was a 
fee charged for the environment and equipment used for providing the 
service to the patient.
The cost of adverse events applied only to patients who had a record 
of serious adverse event(s) during the episode of care. In this study, the 
definition of a serious adverse event was any unwanted or unexpected 
reaction requiring hospitalisation or emergency consultation resulting 
from treatment with chemotherapy for breast cancer. The cost 
components that contributed to the cost of treating adverse events 
were support medicines, laboratory tests, emergency consultations and 
inpatient hospitalisation costs charged per day for the full length of stay. 
The cost of breast cancer treatment and associated adverse events was 
broadly categorised based on the stage at diagnosis, i.e. I, II, III or IV 
according to tumour-node-metastasis (TNM) staging.[5]
Table 1 presents the process that was followed when calculating the 
cost of components.
Time-and-motion studies
The costs of compounding of chemotherapy, administration of 
chemotherapy and outpatient doctor consultations were also 
calculated using data obtained from time-and-motion studies. A data 
collection form was used to record the times taken to perform these 
tasks. The time for each activity was multiplied by the per-minute 
salary.[6] The salaries of the pharmacists, doctors and nurses were 
derived from information published by the Department of Public 
Table 1. Calculation of cost components
Cost component Cost calculation
Chemotherapy medicines Cost of medicines per cycle, which were added to provide the total cost for all treatment cycles
+
Dispensing fee unit cost multiplied by the number of treatment cycles. The dispensing fee was added only 
once for each patient for each day a prescription was handled at the pharmacy
Support medicines Cost of all support medicines
+
Dispensing fee, where applicable
Chemotherapy administration Professional fee per treatment cycle multiplied by the number of treatment cycles
+
Facility fee per treatment cycle multiplied by the number of treatment cycles
Consultations Cost of doctor consultation multiplied by the number of consultations during the episode of care
+
Facility fee per consultation multiplied by the number of consultations during the episode of care
Laboratory tests Sum of unit costs for each test conducted
+
Fee for drawing of blood, calculated for each day laboratory tests were done (usually at every cycle of 
chemotherapy)
Scans and imaging Sum of unit costs for each procedure conducted
+
Sum of facility fee for each procedure conducted
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Service and Administration of SA.[7] For all these studies, the observer 
used a digital stopwatch for accurate capture of the time taken to 
complete a task.
Statistical analysis
Descriptive statistics were used for all variables. Both means and 
medians were used to present cost of treatment owing to some 
outliers that made the means differ from the median. Wilks’ lambda 
test was conducted to test whether there were significant differences 
in costs between the stages of breast cancer. A p-value <0.05 was 
considered to be statistically significant.
Ethical considerations
Ethics approval for the study was obtained from the Research Ethics 
Committee of the University of the Western Cape (ref. no. 14/9/48) 
and the Human Research Ethics Committee of the University of 
Cape Town (HREC ref. no. 824/2014). Patient confidentiality was 
maintained at all times.
Results
The mean (standard deviation) age of the breast cancer patients was 
50 (11.6) years (range 23 - 77 years). The incidences of the various 
stages of breast cancer are reported in Table 2. Of all the stages of 
breast cancer, the highest incidence (49%) was reported for stage 
II at the point of registration, as reflected in Table 2. The lowest 
incidence (7%) was recorded for stage I breast cancer. We found that 
at least 44% of patients were diagnosed with late-stage cancer, i.e. 
stages III and IV combined. Of the patients, 55% presented with a 
pre-existing comorbidity at diagnosis, and of these 27% had two or 
more comorbid conditions. The most frequent comorbidities were 
heart diseases (35.5%), endocrine diseases (12.5%), arthritis and 
pulmonary diseases (8% each) and HIV (5%). Other less common 
comorbidities were depression, eczema and epilepsy.
Cost of chemotherapy
The three aspects of chemotherapy costs that were studied were 
the cost of chemotherapy medicines, the dispensing fee and the 
cost of administration of chemotherapy. The cost of intravenous 
chemotherapy medicines was ZAR761 152 for the 200 patients. The 
cost of chemotherapy and the dispensing fee amounted to ZAR801 311 
for the full sample. The cost of administering chemotherapy to the 
200 patients was ZAR262 749. This cost consisted of a professional 
fee and a facility fee. The dispensing fee of ZAR36 per patient per 
prescription was 5% of the cost of chemotherapy medicines. The 
cost of chemotherapy medicines was 2.9 times more than the cost 
of administering the chemotherapy. This information provided an 
indication of the relationship between the various costs. Of the patients, 
86.5% managed to complete their prescribed chemotherapy treatment 
cycles, and the average cost of treatment of these patients was 1.3 times 
more than the average cost for patients who could not complete their 
treatment, based on the number of treatment cycles received.
Episode-of-care costs
The episode-of-care costs and the contribution of the various cost 
components are summarised in Table 3.
Cost of management of breast cancer
The average costs of managing patients diagnosed with breast cancer 
at GSH are reported in Table 4. The average cost was calculated based 
on each patient’s duration of treatment. The average costs for patients 
who completed and did not complete treatment were categorised 
separately. The average cost of treating a patient who adhered to the 
prescribed chemotherapy protocol for the full duration of treatment 
was ZAR16 259. The average cost for the small proportion (13.5%) 
of the study sample who did not complete the prescribed treatment 
was ZAR12 664 per patient. The combined average cost for the 
200  patients in the study was ZAR15 774. The mean and median 
costs  per patient, based on whether the protocol was completed or 
not, are shown in Table 4.
Of the sample of 200 patients, 16 had adverse events arising from 
chemotherapy that led to additional health resource utilisation. 
The most commonly occurring adverse event was neutropenia. 
The cost of treating a patient with neutropenia was ZAR36  465. 
For the sample of 200 patients, the total cost of managing adverse 
events was ZAR210 128; this cost was attributed to 16 patients 
experiencing a total of 27 adverse events, and included the cost of 
hospitalisation, intravenous antibiotics and anti-emetics. The average 
cost of management of adverse events arising from the various 
treatment modalities was ZAR13 133 per patient. The maximum 
length of hospital stay for the treatment of adverse events was 15 days, 
costing ZAR42 672 for the hospital stay alone.
Time-and-motion results
It took an average of 9.8, 6.7 and 5 minutes to compound 
5-fluorouracil, epirubicin and cyclophosphamide (FEC), epirubicin 
and cyclophosphamide (EC) and paclitaxel (P), respectively. The 
results were used to calculate the cost of compounding of chemo-
therapy by the pharmacist. The cost of compounding for the episode 
of care for 200 patients was ZAR44 671. The cost of chemotherapy 
compounding increased the total cost of medicines by 5.3%.
It took an average of 16.9 minutes of nurses’ time to administer 
chemotherapy. However, the time varied according to the regimen 
Table 2. Clinical characteristics of the study population
Patient characteristics Patients (N=200), n (%) 
Age at diagnosis (years)
18 - 35 22 (11)
36 - 45 46 (23)
46 - 65 113 (56.5)
>65 19 (9.5)
Stage at diagnosis
I 14 (7)
II 98 (49)
III 65 (32.5)
IV 23 (11.5)
Histology
Ductal DCIS, IDC 169 (84.5)
Lobular LCIS, ILC 13 (6.5)
Paget’s disease 1 (0.5)
Mucinous 1 (0.5)
Adenoma NOS 1 (0.5)
Not mentioned 15 (7.5)
Treatment modality
Adjuvant 123 (61.5)
Neo-adjuvant 59 (29.5)
Palliative 18 (9)
Comorbidity
0 91 (45.5)
1 55 (27.5)
≥2 54 (27)
DCIS = ductal carcinoma in situ; IDC = invasive ductal carcinoma; LCIS = lobular 
carcinoma in situ; ILC = invasive lobular carcinoma; NOS = not otherwise stated.
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of chemotherapy received. It took an average of 19.5 minutes 
to administer FEC, 13.8 minutes for EC and 17.3 minutes for P 
(Table  5). The single-dose regimen P took 3.5 minutes more than 
the EC regimen because the infusion rate of the P regimen was slower 
than the EC regimen. These results do not reflect infusion time alone 
but the actual contact time of the nurse with the patient with regard 
to chemotherapy administration.
The average doctors’ time for the first and follow-up consultations 
was 20.5 and 12.1 minutes, respectively. The cost per cycle for the 
former was 1.7 times more that the latter, i.e. ZAR114 v. ZAR68.
Cost of breast cancer based on clinical stage
The mean cost per patient for the various stages is presented in 
Table  6. Analysis of stage at diagnosis revealed that breast cancer 
patients who presented at stages III and IV had the highest cost 
of treatment based on the mean cost per patient per stage. These 
costs included all patients, whether the prescribed protocol of 
chemotherapy was completed or not.
For the cohort of 200 patients, the total cost of treating early-stage 
cancer was ZAR1 670 429 and that of treating late-stage cancer  was 
ZAR1 484 447. The higher total cost of early-stage cancer treatment 
was due to the greater number of patients with early breast cancer 
(n=112) v. late breast cancer (n=88). In this study, early-stage breast 
cancer was categorised as stages I and II disease, while late-stage 
breast cancer was categorised as stages III and IV disease. Wilks’ 
lambda test found significant differences in cost between stages I 
and III, stages I and IV and stages II and III (p<0.001). However, no 
statistically significant difference was observed between stages I and 
II and stages III and IV (p>0.05).
Cost of breast cancer treatment based on age at diagnosis
When patients were grouped according to age, without consideration 
of the type of chemotherapy received or the severity of their cancer, 
the highest number of cases of breast cancer (n=113) was in the 
46 - 65 years age group and the lowest number (n=19) in the oldest 
age group, >65 years (Table 7). The cost of treatment per age group 
is shown in Table 7. The reported differences of the average cost per 
patient in each age group were found not to be statistically significant 
following Wilks’ lambda test (p=0.15).
Discussion
This study focused on the development of a method to determine 
the cost of breast cancer treatment with chemotherapy at GSH. It 
addressed a common limitation of published studies, where the 
development of costing methods is not presented in sufficient detail 
to make methods transparent and reproducible.[8]
The strength of this cost study lies in the determination of actual 
costs of treatment at patient level for an episode of care. Utilisation 
data in the routine setting allowed costing of chemotherapy without 
making assumptions of usage. This was crucial in contrast to other 
studies that make assumptions of cost based purely on the protocols 
being followed.
No direct comparisons between different countries was made in 
this evaluation owing to differences in population, cancer incidence, 
socioeconomic status and health funding systems. An important 
objective of this study was to develop a method for GSH to determine 
the cost of breast cancer for an episode of care. Studies have been 
done in other countries such as Canada[9] and Morocco,[10] but are not 
comparable owing to different costs and methods used.
The major cost driver in this study was scans and imaging, followed 
by a combination of chemotherapy and dispensing fee costs. Procedure 
and facility fees per patient for scans and imaging were higher when 
compared with other component costs. The reason for this could be the 
use of high-technology machines that required a specialist radiographer 
and experienced personnel to interpret the results. The cost of the 
isotopes was included in this analysis. The cost of maintenance of these 
machines is a challenge in developing countries.[11]
The costs of chemotherapy medicines were the second highest of 
all the cost components. A huge variation in cost of chemotherapy 
within the same patient’s episode of care for the same medicines 
and the same dosage was observed. The variation in chemotherapy 
prices was mainly accounted for by the variation in the batch size 
compounded on the particular day.
The costs of breast cancer treatment were dependent on a variety 
of factors, i.e. stage at diagnosis, adverse events and complete 
or incomplete treatment. We found that there was no statistical 
difference between the various age groups when episode-of-care 
costs were compared. In our study, the average age at diagnosis was 
50  years and at least 50% of patients were >50 years old. The age 
group 46 - 65 years accrued the highest cost of treatment owing 
to the high number of patients in this age group (Table 7). Lan et 
al.[12] similarly reported that there were no significant differences in 
median total cost related to patient age (p=0.329).
Table 3. Summary of episode-of-care costs (ZAR) for each component for the treatment of breast cancer at Groote Schuur Hospital
Cost component
Costs for 10 - 12-month period (N=200 patients)
Cost (%) Mean cost per patient SD Median Range 
Chemotherapy and dispensing fee 801 311 (25.4) 4 006 1 635 3 880 544 - 10 653
Chemotherapy administration 262 749 (8.3) 1 313 335 1 404 234 - 3 276
Support medicines 235 425 (7.5) 1 177 738 1 089 116 - 7 385
Consultations 549 562 (17.4) 2 747 736 2 691 897 - 4 784
Laboratory tests (routine) 445 247 (14.1) 2 237 1 166 1 997 447 - 6 840
Scans and imaging (routine) 860 583 (27.3) 4 302 1 674 4 233 527 - 10 064
Total cost 3 154 877 (100) - - - -
SD = standard deviation.
Table 4. Average cost of management of breast cancer (ZAR) 
per patient at Groote Schuur Hospital
Cost per patient 
over ~10 - 12-month 
treatment period
Total costMean (SD) Median
Complete protocol (n=173) 16 259 (6 077) 15 551 2 812 929
Incomplete protocol (n=27) 12 664 (6 417) 12 252 341 948
All patients (N=200) 15 774 15 295 3 154 877
Adverse events (n=27) 7 782 6 870 210 128
SD = standard deviation.
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It was found in the present study that the stage of cancer at diagnosis 
was probably the most crucial parameter in defining the cost of 
treatment. The mean cost of treatment for stage I was significantly 
lower than the cost for more advanced stages. An early diagnosis 
of cancer (particularly stage I) therefore results in a lower cost of 
treatment compared with late-stage breast cancer (stages III and 
IV). Another study[12] has also reported that the progress of disease 
was the main factor influencing the cost of treatment, because 
medical intervention was decided on according to the extent of 
spread and stage of disease. The cost of late-stage treatment was 
increased by the more likely occurrence of adverse events, treatment 
complications and palliative care.[12] As adverse effects contribute to 
extensive resource use in hospital, it is important that these costs are 
considered.[13] Our study, like that of Lan et al.,[12] showed that costs 
of treatment are reduced when breast cancer is diagnosed at an early 
stage and that age at diagnosis did not significantly influence the cost 
of treatment.
To improve the accuracy of the costing, time-and-motion studies 
were conducted. The cost of compounding chemotherapy increased 
the total cost of chemotherapy by 5.3%. It appears that the UPFS 
did not account for the costs associated with the compounding of 
chemotherapy. Our study therefore considered this additional cost. 
This cost component should be accounted for, as it is an important 
cost of treatment.[6]
With regard to the time-and-motion studies, the time recordings 
were conducted by the researcher and not self-reported. This 
approach reduced the risk of bias and systematic misreporting of 
time spent. The recording of actual times provided an opportunity to 
measure actual resource use as opposed to calculating costs from the 
protocol-based method.[14]
Study limitations
While the sample size of 200 patients was sufficient to develop a 
costing method for breast cancer at GSH, the sample size may not 
be large enough to conduct detailed statistical analyses owing to the 
smaller sample sizes in the sub-population groups.
Conclusions
A method of costing breast cancer treatment at GSH was successfully 
developed. The costs associated with breast cancer management per 
episode of care were quantified at GSH according to the treatment 
protocols used at the hospital. The average cost per patient for an 
episode of care was ZAR15 774, and the average cost of managing an 
adverse event was ZAR7 782. These results may not be generalisable 
to other public hospitals. Understanding the total cost of care for 
breast cancer is important in SA owing to the high prevalence of 
breast cancer relative to other cancers and budgetary constraints. 
With the advent of National Health Insurance in SA, understanding 
the total cost of care will become even more important to improve 
budget allocation. The mean cost of treatment for stage I breast 
cancer was significantly lower than that for the more advanced stages. 
An early diagnosis of cancer (particularly stage I) therefore results 
Table 5. Time-and-motion study results
Task Mean time per cycle (min) Mean cost per cycle (ZAR)
Compounding of chemotherapy Pharmacists’ time
FEC 9.8 44
EC 6.7 31
P 5.0 23
Consultation Doctors’ time
First visit 20.5 114
Follow-up 12.1 68
Administration of chemotherapy Nurses’ time
FEC 19.5 39
EC 13.8 27
P 17.3 34
Administration of chemotherapy Doctors’ time
Updating patient folder/responding to queries 1.3 7
F = 5-fluorouracil; E = epirubicin; C = cyclophosphamide; P = paclitaxel.
Table 6. Cost of treatment (ZAR) per stage of breast cancer for all patients
Stage at diagnosis Total cost per stage Mean cost per patient per stage Range
I 191 050 (n=14) 13 646 5 611 - 24 419
II 1 479 379 (n=98) 15 095 3 480 - 37 705
III 1 096 615 (n=65) 16 871 3 922 - 38 627
IV 387 832 (n=23) 16 862 5 867 - 36 569
Table 7. Cost of treatment (ZAR) per age group
Age at diagnosis (years) Cost per age group Cost per patient per age group Range
18 - 35 (n=22) 358 815 16 309 5 635 - 33 232
36 - 45 (n=46) 737 405 16 030 4 047 - 40 932
46 - 65 (n=113) 1 782 553 15 774 2 821 - 39 076
>65 (n=19) 280 463 14 761 6 345 - 22 294
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in a lower cost of treatment compared with late-stage breast cancer 
(stages III and IV).
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